ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") today announces highlights and new milestones reached during the 2024 calendar year.  The company remains committed to pioneering ...

REPAY , a leading provider of vertically-integrated payment solutions, today announced a strategic integration with Worth, the all-in-one fintech platform for underwriting and onboarding workflow ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...

Adstiladrin showed a 53% CR rate at three months in its pivotal trial, although, that fell to 24% at 12 months, while Anktiva's efficacy was very close to TAR-200, with an initial rate of 84% that ...

The combination of Anktiva (N-803) and BCG has emerged as a promising treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), demonstrating high complete response rates and durable ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...